Jan, 11 2018 11:46 JST

Source: Eisai

Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China


TOKYO, Jan, 11 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has completed construction of a new oral solid dose (OSD) production facility and an administration building at the site of its new Suzhou plant located within the Suzhou Industrial Park.

Aiming to further expand its contribution to patients in China, Eisai has been working to establish a new Suzhou plant on a new industrial site more than five times larger than the current Suzhou Plant (OSD production facility) to further strengthen the stable supply chain as well as improve production efficiency.

ECI established a parenteral facility in November 2014, where it manufactures the injection formulation of Methycobal. The newly completed OSD production facility stands three floors aboveground and contains floor space of approximately 20,240 m2, and its production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) is approximately double that of the current Suzhou Plant. Operations are expected to commence in the second half of fiscal 2018, and the new OSD facility will handle the formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic Chinese market. The current plant will be closed after operations fully commence at the new Suzhou Plant's OSD production facility.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. Through the completion of the OSD production facility at the new Suzhou Plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.


About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Eisai Co., Ltd.
Public Relations Department
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC
September 05 2018 14:28 JST
 
Eisai Receives Approval for Partial Label Change for Vascular Embolization Device DC Bead
September 03 2018 14:50 JST
 
Eisai's LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea
August 30 2018 09:36 JST
 
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab
August 29 2018 10:25 JST
 
Eisai: Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent BELVIQ
August 28 2018 09:11 JST
 
Eisai: European Commission Grants Marketing Authorization for LENVIMA (Lenvatinib)
August 23 2018 08:00 JST
 
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech
July 31 2018 14:13 JST
 
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
July 31 2018 10:27 JST
 
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018
July 26 2018 10:34 JST
 
Eisai and Biogen Present Detailed Results from Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at AAIC 2018
July 26 2018 08:01 JST
 
More Press release >>

Latest Press Release


More Latest Release >>